Showing results (41-50 of 100) with videos related to
Sort By:
Pageof 10
Applied Health Economics and Health Policy|April 24, 2014
Assessing medication adherence and healthcare utilization and cost patterns among hospital-discharged patients with schizoaffective disorderSudeep Karve, Michael Markowitz, Dong-Jing Fu, et al.Schizophrenia Research|May 28, 2026
Psychometric analysis of speech-based digital biomarkers of alogia symptoms in treatment resistant schizophrenia: Comparison with clinical ratings of expressive negative symptomsJean-Pierre Lindenmayer, Anzalee Khan, Beverly J Insel, et al.Schizophrenia Research|September 11, 2010
Cognitive and symptomatic predictors of functional disability in schizophreniaSyed Shamsi, Adam Lau, Todd Lencz, et al.Journal of Clinical Psychopharmacology|June 21, 2016
Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective DisorderDong-Jing Fu, Ibrahim Turkoz, R Bruce Simonson, et al.Journal of Clinical Psychopharmacology|May 20, 2024
Sustained Treatment Response and Global Improvements With Long-term Valbenazine in Patients With Tardive DyskinesiaChristoph U Correll, Leslie Citrome, Carlos Singer, et al.Schizophrenia Research|March 3, 2009
Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorderRobert C Smith, Jean-Pierre Lindenmayer, John M Davis, et al.Asian Journal of Psychiatry|August 14, 2016
Cabergoline can induce mania with psychotic features in bipolar I disorder: a case reportChiara Rovera, Laura Cremaschi, Amod Thanju, et al.Psychiatric Services (Washington, D.C.)|March 1, 2008
A randomized controlled trial of cognitive remediation among inpatients with persistent mental illnessJean-Pierre Lindenmayer, Susan Regina McGurk, Kim T Mueser, et al.Schizophrenia Research|October 31, 2012
Relationship between metabolic syndrome and cognition in patients with schizophreniaJean Pierre Lindenmayer, Anzalee Khan, Saurabh Kaushik, et al.The Journal of Clinical Psychiatry|May 25, 2010
A randomized, double-blind, placebo-controlled study of 2 dose ranges of paliperidone extended-release in the treatment of subjects with schizoaffective disorderCarla M Canuso, Jean-Pierre Lindenmayer, Colette Kosik-Gonzalez, et al.Pageof 10